Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olisens-Aniridia: AGANIRSEN eye drops for corneal neovascularization in aniridia-associated keratopathy
2025-522609-39-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Jan 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aganirsen in corneal neovascularization (CNV) and Aniridia Associated Keratopathy (AAK), sponsored by University of Cologne. Primary endpoint: Relative change of corneal area covered by corneal neovascularization. Planned start Jan 2026; status: authorised.
02
Drugs
aganirsen
03
Conditions
corneal neovascularization (CNV)Aniridia Associated Keratopathy (AAK)
Beyond the preview
Go deeper on 2025-522609-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522609-39-00.